Product Description
Tioguanine (TG) is an antimetabolite which may be regarded as an alternative to azathioprine (AZA)/mercaptopurine (MP) in patients with inflammatory bowel diseases. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/12940925/)
Mechanisms of Action: DNA Synthesis Inhibitor,RNA Synthesis Inhibitor,GPAT Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Belgium | Brazil | Canada | Chile | Colombia | Czech | Ecuador | Egypt | Estonia | France | Germany | Greece | Hong Kong | India | Ireland | Italy | Jordan | Korea | Lithuania | Malaysia | Malta | Netherlands | New Zealand | Pakistan | Peru | Poland | Romania | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Thailand | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay
Approved Indications: None
Known Adverse Events: None
Company: Douglas Pharmaceuticals
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count: 2
Highest Development Phases
Phase 1: Colitis, Ulcerative|Oral Ulcer|Proctitis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
ACTRN12624001448538 | P1 |
Not yet recruiting |
Oral Ulcer|Colitis, Ulcerative |
2025-06-30 |
|
ACTRN12623001337662 | P1 |
Not yet recruiting |
Oral Ulcer|Proctitis |
2024-04-30 |